Management of Dyspareunia
For postmenopausal women with dyspareunia, offer local low-dose vaginal estrogen as first-line therapy, as it effectively treats vulvovaginal dryness and pain during intercourse with an excellent safety profile 1.
Initial Assessment Framework
When evaluating dyspareunia, distinguish between:
- Superficial pain (entry/introital) versus deep pain (with deep penetration)
- Provoked (occurs only with penetration) versus spontaneous symptoms
- Timing: New onset, longstanding, or worsening pattern
Key examination findings to identify:
- Vulvar inspection: Look for porcelain-white plaques (lichen sclerosus), erythema, fissures, or ecchymosis 2
- Vestibular assessment: Cotton swab test for localized tenderness suggesting vestibulodynia 3, 4
- Vaginal examination: Assess pH, epithelial integrity, moisture, and elasticity
- Pelvic floor evaluation: Palpate for muscle hypertonicity, trigger points, or guarding that limits penetration 1, 4
- Bimanual exam: Assess for deep tenderness suggesting endometriosis, pelvic congestion, or other pelvic pathology 5, 4
Treatment Algorithm by Phenotype
For Genitourinary Syndrome of Menopause (GSM)
Primary recommendation: Local low-dose vaginal estrogen (cream, tablet, or ring) improves dryness, irritation, and dyspareunia with no increase in serum estradiol levels or endometrial cancer risk 1.
Alternative hormonal options:
- Vaginal DHEA (prasterone): Moderate recommendation for vulvovaginal dryness and dyspareunia, maintains postmenopausal serum hormone levels 1, 6
- Ospemifene: Oral selective estrogen receptor modulator option 1
The choice between these agents should prioritize patient preference, dexterity for application, and consistent use ability rather than following a rigid stepwise progression 1.
For Pelvic Floor Dysfunction
When examination reveals muscle hypertonicity, tenderness, or guarding, refer to pelvic floor physical therapy 1, 4. This addresses myofascial trigger points, improves muscle relaxation and elasticity, and enhances motor control 1. Pelvic floor dysfunction commonly coexists with GSM and requires concurrent treatment.
For Lichen Sclerosus
When porcelain-white plaques, ecchymosis, or fissuring are present, this represents a distinct dermatologic condition requiring topical corticosteroids 2. Dyspareunia occurs with erosions, fissures, or introital narrowing. This condition can persist and requires long-term monitoring.
For Deep Dyspareunia
Deep pain with penetration suggests pathology beyond the vaginal introitus. Consider:
- Endometriosis: Laparoscopic excision of deep lesions improves both deep dyspareunia and quality of sexual life more effectively than medical therapy alone 5
- Pelvic congestion syndrome: Treat with pelvic vein embolization 5
- Interstitial cystitis: Intravesical therapy may be effective 5
Imaging and specialist referral are warranted when bimanual examination reveals deep tenderness or masses 4.
Adjunctive Measures for All Phenotypes
- Lubricants and moisturizers: Recommend for all patients regardless of hormonal therapy 3, 4
- Irritant avoidance: Eliminate potential vulvar irritants 4
- Psychosocial support: Refer to credentialed sex therapist when psychosocial or sexual health concerns are prominent 1, 3
Critical Pitfalls to Avoid
Do not normalize dyspareunia as an expected part of menopause or aging 7. Women often experience symptoms for months to years before accurate diagnosis 8. Proactively ask about sexual pain using direct questioning or written questionnaires 3.
Do not assume all postmenopausal dyspareunia is GSM. Vestibular pain, dermatologic conditions (lichen sclerosus), pelvic floor dysfunction, and deep pelvic pathology require different treatments 4. The examination must systematically evaluate from vulva to deep pelvis.
Do not overlook pelvic floor hypertonicity. When present, hormonal therapy alone will be insufficient 1, 4. Concurrent pelvic floor physical therapy is essential for treatment success.
In lichen sclerosus, do not mistake ecchymosis for abuse, though the two can coexist through Koebnerization 2. This condition requires specific topical corticosteroid treatment, not hormonal therapy.